design-clinical-trial-protocol

Design Clinical Trial Protocol

Design a rigorous clinical trial protocol by defining the study question, selecting the appropriate design, specifying endpoints, calculating required sample size, and planning for regulatory compliance from the outset.

Why This Is Best Practice

Adopted by: FDA, EMA, PMDA, and all major regulatory agencies require clinical trials submitted for drug approval to follow ICH E6 GCP standards. CONSORT 2010 reporting guidelines are mandated by >600 journals including NEJM, Lancet, JAMA, and BMJ. WHO International Clinical Trials Registry Platform (ICTRP) requires prospective registration of all clinical trials. Impact: Schulz et al. (2010) CONSORT analysis showed that trials with adequate allocation concealment had 30-40% smaller (more accurate) effect estimates than poorly concealed trials, demonstrating that design quality directly affects result validity. Prospective registration (ClinicalTrials.gov, ISRCTN) — compared to retrospective registration — reduces outcome-switching bias, which Dwan et al. (2008) found in up to 62% of published trials.

Steps

1. Define the research question using PICO

Specify:

• Population: precise inclusion and exclusion criteria (demographics, disease stage, comorbidities, washout requirements)
• Intervention: treatment, dose, route, duration
• Comparator: placebo, standard of care, active comparator
• Outcomes: primary endpoint (one only; drives the sample size calculation) and secondary endpoints (pre-specified, not data-dredged)

The primary endpoint must be:

• Clinically meaningful (not a surrogate unless validated)
• Measurable with a validated instrument
• Assessable within the planned follow-up period

2. Select the study design

Match design to the research question and phase:

• Phase I: dose escalation, safety, pharmacokinetics — 3+3 design or model-based (BOIN, CRM); n=20-80
• Phase II: preliminary efficacy, dose selection — randomized or single-arm; n=50-300
• Phase III: confirmatory efficacy — randomized, double-blind, controlled; n=100-10,000+
• Phase IV: post-approval safety and effectiveness — observational or randomized

For interventional trials: randomized controlled trial (RCT) is the gold standard for causal inference.

Special designs:

• Adaptive design: pre-specified rules for sample size re-estimation or dose dropping at interim; requires FDA pre-agreement
• Crossover design: participants receive both treatments sequentially; efficient but only for stable, reversible conditions
• Cluster randomization: groups (hospitals, schools) rather than individuals randomized; requires ICCs in sample size calculation

3. Plan randomization and blinding

Randomization strategy:

• Simple randomization: acceptable for large trials (n>200); vulnerable to imbalance in smaller trials
• Block randomization (recommended): blocks of 4-6 ensure balance over time; block size should be concealed from investigators
• Stratified randomization: balance key prognostic factors (disease severity, site, age) across arms; use for multi-site trials or trials with strong covariates
• Use a validated randomization system (REDCap, IVRS/IWRS)

Blinding level:

• Double-blind: participants AND assessors unaware of allocation — required for subjective endpoints
• Single-blind: assessor-blinded only; acceptable for objective endpoints (mortality)
• Open-label: no blinding; acceptable when blinding is impossible; use blinded outcome adjudication

4. Calculate sample size

Sample size calculation must be documented in the protocol:

For two-group parallel trial (continuous endpoint):
n per group = 2σ²(Zα/2 + Zβ)² / δ²

Where:
σ = standard deviation of outcome
δ = minimum clinically important difference (MCID)
Zα/2 = 1.96 (two-sided α = 0.05)
Zβ = 0.84 (power = 80%) or 1.28 (power = 90%)

Add 10-20% for expected dropout/attrition.

Source the MCID and σ from pilot data, literature, or regulatory precedent — not arbitrary choices.

5. Plan the statistical analysis

Pre-specify in a Statistical Analysis Plan (SAP) before unblinding:

• Primary analysis population: Intent-to-Treat (ITT; all randomized) as the primary; Per-Protocol as sensitivity analysis
• Handling missing data: pre-specify multiple imputation or mixed-model for repeated measures (MMRM)
• Multiplicity adjustment: if multiple primary endpoints or interim analyses, specify Bonferroni, Holm, or alpha-spending function (O'Brien-Fleming)
• Interim analyses: pre-specify stopping rules (futility and efficacy boundaries) with Data Safety Monitoring Board (DSMB) review

6. Address regulatory and ethical requirements

Before the first participant is enrolled:

• Protocol registration: ClinicalTrials.gov (US), EudraCT (EU), ISRCTN — before enrollment begins
• IRB/Ethics Committee approval: submit protocol, informed consent form, investigator brochure
• Informed consent: document process; ensure comprehension beyond signature
• DSMB: required for trials with mortality endpoints or vulnerable populations
• IND/CTA filing: required for investigational drugs before Phase I

Common Mistakes

• Composite primary endpoint designed to inflate event rate rather than measure a clinically coherent outcome: Components must be similarly clinically important (MACE = MI + stroke + CV death is coherent; combining death with "hospitalization for any reason" is not).
• Sample size not powered for the primary endpoint: Powering for secondary endpoints produces a statistically underpowered primary analysis.
• Retrospective registration: Trials registered after enrollment begins have lower credibility and are rejected by CONSORT-compliant journals.

When NOT to Use

• Rare diseases with <50 available patients: consider N-of-1 designs, Bayesian adaptive designs, or master protocols (basket/umbrella trials).